Effects of Tocilizumab (RoACTEMRA) on biomarkers in synovial tissue of patients with rheumatoid arthritis - Mode of Action Tocilizumab

Academisch Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•males/females suffering form RA according to the ACR/EULAR 2010 classification criteria
•active disease das 28 * 3.2 despite adequate MTX treatment
•ARA functional classes I, II and III
•* 18 and * 70 years of age
•stable MTX treatment (5 - 30 mg/week) for at least 28 days
•inflamed knee, ankle or wrist joint

•Breastfeeding;
•Subjects who are impaired, incapacitated, or incapable of completing study related assessments;
•Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus erythematosus);
•Subjects who have previously received treatment with tocilizumab;
•Current use of oral corticosteroids (if exceeding a prednisone equivalent of 10 mg daily) or DMARDs other than MTX; intra-articular injections of corticosteroids 28 days or less before inclusion.
•Current use of TNF blocking agents, such as etanercept, adalimumab, infliximab, golimumab or certlizumab. Washout periods are depending on pharmacokinetic profile of the various agents
•Rituximab en abatacept washout
•Subjects with active vasculitis of a major organ system with the exception of rheumatoid nodules.

发起方